Industry Urged To Share Potential Regulatory Challenges To Decentralized Manufacturing

In a world where pharmaceuticals could be manufactured with no fixed address, industry and regulatory authorities must work together to interpret site-based compliance requirements, expert says. New concepts like the MHRA-proposed hub-and-spokes model could play key role.

Distributed pharmaceutical manufacturing
time to talk about decentralization • Source: Alamy

More from Manufacturing

More from Compliance